

# PROVIDER Update



CONTRACTUAL | FEBRUARY 16, 2024 | UPDATE 24-173 | 5 PAGES

## New: 1st Quarter 2024 Injectable Medication HCPCS/DOFR Crosswalk

### Use the updates for dates of service on and after April 22, 2024

On January 9, 2024, the Health Net\* Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates, effective April 22, 2024, are listed on pages 2-5 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net Provider Participation Agreement (PPA).

The update includes:

- 20 new injectable medications to be added to the DOFR crosswalk.
- 17 updates and changes to injectable medication procedure codes.
- 1 update category
- 12 updates for new generic drugs.

#### Additional information

Relevant sections of Health Net's provider operations manual will be revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library after logging in to the provider portal at [provider.healthnetcalifornia.com](https://provider.healthnetcalifornia.com) > *Provider Library* under Quick Links or go directly to [providerlibrary.healthnetcalifornia.com](https://providerlibrary.healthnetcalifornia.com).

If you have questions regarding the information contained in this update, contact the Provider Services Center by email at [provider\\_services@healthnet.com](mailto:provider_services@healthnet.com), by phone or through the Health Net provider website as listed in the right-hand column.

#### THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Participating Physician Groups

#### LINES OF BUSINESS:

- IFP
  - Ambetter HMO
  - Ambetter PPO
- Employer Group
  - HMO/POS
  - PPO
- Medicare Advantage (HMO/PPO) (Wellcare By Health Net)
- Medi-Cal
  - Amador
  - Calaveras
  - Inyo
  - Los Angeles
  - Molina
  - Mono
  - Sacramento
  - San Joaquin
  - Stanislaus
  - Tulare
  - Tuolumne

#### PROVIDER SERVICES

[provider\\_services@healthnet.com](mailto:provider_services@healthnet.com)

#### Ambetter from Health Net IFP

**Ambetter PPO** – 844-463-8188

**Ambetter HMO** – 888-926-2164

**Health Net Employer Group HMO, POS & PPO** – 800-641-7761

**Medicare (individual & employer group) (Wellcare By Health Net)** – 800-929-9224

**Medi-Cal (including CS and ECM providers)** – 800-675-6110

#### PROVIDER PORTAL

[provider.healthnetcalifornia.com](https://provider.healthnetcalifornia.com)

#### PROVIDER COMMUNICATIONS

[provider.communications@healthnet.com](mailto:provider.communications@healthnet.com)

\*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved. CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at [provider.communications@healthnet.com](mailto:provider.communications@healthnet.com) indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

## Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved by the Health Net P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from participating physician groups (PPGs).

### New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
Q5132	Abrilada™	Injection, adalimumab-afzb , biosimilar, 10 mg- 0069-0347-02; 40 mg 0069-0319-01.	Therapeutic injection	
Q5132	Abrilada™	Injection, adalimumab-afzb , biosimilar, 20, 40 mg - 00069-0333-02; 00069-0325-01; 00069-0325-02; 00069-0328-02; 00025-0325-02 ; 00025-0328-02; 00025-0333-02; 00025-0325-01	Self-injectable	
J3590	Adzyna	Adamts13 recombinant-krhn	Therapeutic injection	
J3490	Aphexda™	Motixafortide for injection, for subcutaneous use	Therapeutic injection	Chemotherapy adjunctive <sup>1</sup>
C9159	Balfaxar®	Injection, prothrombin complex concentrate (human), per IU of Factor IX activity	Therapeutic injection	Blood/blood products for hemophilia
J3590	Bimzelx®	Bimekizumab-bkzx	Self-injectable	
J3590	Casgevy™	Exagamglogene autotemcel, suspension for intravenous infusion	Therapeutic injection	
J3590	Cosentyx uno	Secukinumab subcutaneous solution auto-injector 300 mg/2 ml	Self-injectable	
J3380	Entyvio® (subcutaneous)	Vedolizumab solution pen-injector 108 mg/0.68 ml 64764-0108-20; 64764-0108-21	Self-injectable	
Q5131	Idacio®	Adalimumab-aacf	Self-injectable	
J3590	Lyfgenia®	Lovotibeglogene autotemcel suspension for intravenous infusion	Therapeutic injection	
J9999	Loqtorzi™	Toripalimab-tpzi IV solution	Therapeutic injection	Chemotherapy <sup>1</sup>
J3590	OmvoH™	Mirikizumab-mrkz Intravenous injection 00002-7575-01	Therapeutic injection	

## Additions to injectable medication HCPCS/DOFR crosswalk, *continued*

### New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Omvo <sup>™</sup>	Mirikizumab-mrkz subcutaneous injection 00002-8011-01; 00002-8011-27	Self-injectable	
J9324	Pemrydi Rtu <sup>®</sup>	Injection, pemetrexed, 10 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
J3590	Pombiliti <sup>™</sup>	Cipagluco <sup>™</sup> alfa-atga for IV solution	Therapeutic injection	
J1246	Unituxin <sup>®</sup>	Injection, Dinutuximab, 0.1 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
J3490	Wegovy <sup>®</sup>	Semaglutide (weight management) solution	Self-injectable	
J3490	Zepbound <sup>™</sup>	Tirzepatide (weight management) solution	Self-injectable	
J3590	Zymfentra	Infliximab-dyyb injection, for subcutaneous use	Self-injectable	

<sup>1</sup>If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

### Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
J0402	Abilify Asimtufii <sup>®</sup>	Aripiprazole IM ER Susp Prefilled Syringe	Replaces C9152
J0391	Artesunate	Injection, artesunate, 1 mg	Replaces J3590
J0184	Barhemsys <sup>®</sup>	Amisulpride (antiemetic) IV solution 10 mg/4 ml	Replaces C9153
J0576	Brixadi <sup>™</sup>	Buprenorphine extended release subcutaneous injection	Replaces G2074
J9286	Columvi <sup>™</sup>	Glofitamab-gxbm injection for intravenous (IV) infusion	Replaces J3590
C9160	Daxxify <sup>®</sup>	Injection, daxibotulinumtoxin <sup>™</sup> -lanm, 1 unit	Replaces J3590
J1413	Elevidys	Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose	Replaces J3590

**Updates/changes to injectable medication procedure codes or medications, *continued***

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Comment</b>
<b>J2508</b>	Elfabrio®	Pegunigalsidase alfa-iwxj injection	Replaces J3590
<b>C9165</b>	Elrexio™	Elranatamab-bcmm Subcutaneous solution 44 mg/1.1 ml	Replaces J3590
<b>C9162</b>	Izervay™	Injection, avacincaptad pegol, 0.1 mg	Replaces J3490
<b>J0217</b>	Lamzede®	Injection, velmanase alfa-tycv, 1 mg	Replaces J3590
<b>J1304</b>	Qalsody™	Tofersen Intrathecal Soln 100 mg/15 ml (6.7 mg/ml)	Replaces C9157
<b>J1412</b>	Rocktavian™	Valoctocogene roxaparvovec-rvox	Replaces J3590
<b>J9333</b>	Rystiggo®	Injection, rozanolixizumab-noli, 1 mg	Replaces J3590
<b>J2781</b>	Syfovre™	Pegcetacoplan injection, for intravitreal use	Replaces J3490
<b>J2679</b>	Uzedly™	Risperidone subcutaneous ER suspension prefilled syringe 200 mg/0.56 ml	Replaces C9158
<b>J9334</b>	Vyvgart® Hytrulo	Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc	Replaces J3590

**Category changes**

The following medication has been approved by the Health Net Pharmacy and Therapeutics Committee to correct the Secondary Category listed below.

<b>HCPCS</b>	<b>Drug name</b>	<b>Generic name</b>	<b>Primary category</b>	<b>Secondary category</b>
<b>J2562</b>	Mozobil® 24 mg/1.2 ml solution	Plerixafor injection	Therapeutic injection	Chemotherapy adjunctive <sup>1</sup>

## New generic injectable medications

The following medications have been approved by the Health Net Pharmacy and Therapeutics Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table

HCPCS	Drug name	Generic name	Primary category	Secondary category
<b>J1939</b>	Bumetanide	Injection, bumetanide, 0.5 mg	Therapeutic injection	
<b>J9052</b>	Carmustine	Injection, carmustine (accord), not therapeutically equivalent to J9050, 100 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
<b>J0688</b>	Cefazolin	Injection, cefazolin sodium (hikma), not therapeutically equivalent to J0690, 500 mg	Therapeutic injection	Home health/infusion <sup>2</sup>
<b>J9072</b>	Cyclophos-phamide	Injection, cyclophosphamide, (Dr. Reddy's), 5 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
<b>J0873</b>	Daptomycin	Injection, daptomycin, not therapeutically equivalent to J0878, 1 mg	Therapeutic injection	Home health/infusion <sup>2</sup>
<b>J2679</b>	Fluphenazine	Injection, fluphenazine HCl, 1.25 mg	Therapeutic injection	
<b>J1596</b>	Glycopyrrolate	Injection, glycopyrrolate, 0.1 mg	Therapeutic injection	
<b>J3425</b>	Hydroxo-cobalamin	Injection, hydroxocobalamin, 10 mcg	Therapeutic injection	
<b>J9172</b>	Docetaxel	Injection, docetaxel (ingenus), not therapeutically equivalent to J9171, 1 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
<b>J9255</b>	Methotrexate	Injection, methotrexate (accord), not therapeutically equivalent to J9250 and J9260, 50 mg	Therapeutic injection	Chemotherapy <sup>1</sup>
<b>J2404</b>	Nicardipine	Injection, nicardipine, 0.1 mg	Therapeutic injection	
<b>J9258</b>	Paclitaxel protein-bound particles	Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to J9264, 1 mg	Therapeutic injection	Chemotherapy <sup>1</sup>

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at [www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html](http://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html).

<sup>1</sup>If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

<sup>2</sup>When administered by a nurse in a home setting.